VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Esperion Therapeutics, Inc. (ESPR) Total Return Calculator with Dividends Reinvested

Esperion Therapeutics, Inc.

Popular:

The total return for Esperion Therapeutics, Inc. (ESPR) stock is +260.55% over the past 12 months. So far it's down 15.36% this year. The 5-year total return is -85.91%, meaning $10,000 invested in ESPR stock 5 years ago would be worth $1,409 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in ESPR 1 year ago, it would be worth $35,170 today — you'd have gained $25,170.

With Dividends Reinvested$35,170+251.70%

Price Only (No DRIP)$35,170+251.70%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in ESPR

1Y$36,055+$26,055 (+260.5%)260.5% CAGR

3Y$23,259+$13,259 (+132.6%)32.5% CAGR

5Y$1,409-$8,591 (-85.9%)-32.4% CAGR

10Y$2,042-$7,958 (-79.6%)-14.7% CAGR

15Y$2,166-$7,834 (-78.3%)-9.7% CAGR

20Y$2,166-$7,834 (-78.3%)-7.4% CAGR

30Y$2,166-$7,834 (-78.3%)-5.0% CAGR

Esperion Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading ESPR total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-15.36%	—	-15.36%	—	$8,464
1Y	+260.55%	260.55%	+260.55%	—	$36,055
3Y	+132.59%	32.49%	+132.59%	—	$23,259
5Y	-85.91%	-32.43%	-85.91%	—	$1,409
10Y	-79.58%	-14.69%	-79.58%	—	$2,042
15Y	-78.34%	-9.70%	-78.34%	—	$2,166
20Y	-78.34%	-7.36%	-78.34%	—	$2,166
30Y	-78.34%	-4.97%	-78.34%	—	$2,166

Risk & Highlights

Best Year+411.18%2017

Worst Year-81.96%2021

Max Drawdown-53.19%2025-12-11 → 2026-04-21

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-9.70%	-9.70%	—	+0.41%	-10.1pp
2025	+68.18%	+68.18%	—	+16.64%	+51.5pp
2024	-24.66%	-24.66%	—	+24.00%	-48.7pp
2023	-48.80%	-48.80%	—	+24.81%	-73.6pp
2022	+20.04%	+20.04%	—	-19.95%	+40.0pp

ESPR outperformed the S&P 500 by 230.18pp over the past year (+260.55% vs +30.37%).

Loading summary...

ESPR Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
ESPREsperion Therapeutics, Inc.	$653M	+35.9%	-15.4%	+260.5%	—	+132.6%	-85.9%	-79.6%
MDGLMadrigal Pharmaceuticals, Inc.	$12.3B	+4.5%	-9.9%	+79.0%	—	+73.2%	+310.1%	+3921.5%
EWTXEdgewise Therapeutics, Inc.	$3.8B	+9.5%	+49.8%	+145.0%	—	+260.1%	+21.7%	+18.6%
PRTAProthena Corporation plc	$567M	+1.6%	+14.5%	+44.4%	—	-86.3%	-57.2%	-73.0%
RAREUltragenyx Pharmaceutical Inc.	$2.6B	+12.9%	+10.7%	-21.8%	—	-44.5%	-77.2%	-59.4%
ACADACADIA Pharmaceuticals Inc.	$3.9B	+2.2%	-13.7%	+52.4%	—	+4.7%	+7.1%	-22.9%
AMRNAmarin Corporation plc	$309M	+1.0%	+8.2%	+45.8%	—	-44.2%	-83.9%	-54.5%
AKROAkero Therapeutics, Inc.	$4.5B	—	—	+27.7%	—	+20.1%	+100.0%	+198.3%
LNTHLantheus Holdings, Inc.	$5.9B	+16.5%	+35.3%	+13.1%	—	-4.0%	+314.2%	+4192.5%
NUVLNuvalent, Inc.	$7.5B	+0.1%	+1.5%	+53.5%	—	+171.2%	+446.1%	+446.1%
HALOHalozyme Therapeutics, Inc.	$7.7B	+2.5%	-7.3%	-7.1%	—	+115.3%	+37.0%	+570.7%

Compare:ESPR vs MDGL ESPR vs EWTX ESPR vs PRTA ESPR vs MDGL vs EWTX

About ESPR Dividend Returns

Esperion Therapeutics, Inc. (ESPR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of ESPR over the past year?

Esperion Therapeutics, Inc. (ESPR) delivered a return of 260.55% over the past year. Since ESPR does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in ESPR be worth today?

A $10,000 investment in Esperion Therapeutics, Inc. one year ago would be worth $36,055 today, representing a gain of $26,055.

Q3Does ESPR pay dividends?

Esperion Therapeutics, Inc. (ESPR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ESPR, the total return equals the price-only return.

Q4Did ESPR beat the S&P 500?

Yes, Esperion Therapeutics, Inc. (ESPR) outperformed the S&P 500 by 230.18 percentage points over the past year. ESPR delivered a total return of 260.55%, compared to the S&P 500's 30.37%. This 230.18pp alpha means investors in ESPR earned more than a passive S&P 500 index fund.

Q5What is ESPR's worst drawdown?

Esperion Therapeutics, Inc. (ESPR) experienced a maximum drawdown of -53.19% over the past year, declining from its peak on 2025-12-11 to its trough on 2026-04-21. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is ESPR's long-term total return over 10, 20, or 30 years?

Here are Esperion Therapeutics, Inc. (ESPR)'s long-term returns with dividends reinvested. Over 10 years, the total return is -79.6% (-14.7% CAGR) — $10,000 would have grown to $2,042. Over 20 years: -78.3% total return (-7.4% CAGR) — $10,000 → $2,166. Over 30 years: -78.3% total return (-5.0% CAGR) — $10,000 → $2,166. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was ESPR's best and worst year?

Esperion Therapeutics, Inc.'s best calendar year was 2017 with a total return of 411.2%. Its worst year was 2021 with a total return of -82.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 493.1 percentage points.